ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2006--InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug delivery company, today announced the U.S. Food and Drug Administration has accepted for filing and comprehensive review, InSite Vision’s NDA for AzaSite (azithromycin 1% ophthalmic solution), indicated for the treatment of bacterial conjunctivitis. AzaSite is formulated with “DuraSite,” InSite Vision’s patented drug delivery vehicle which enhances the retention time of the antibiotic on the surface of the target tissue
